Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 19 2021 - 04:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2021
Commission File Number: 001-40212
Connect Biopharma Holdings Limited
(Translation of registrants name into English)
Science and
Technology Park
East R&D Building, 3rd Floor
6 Beijing West Road, Taicang
Jiangsu Province, China 215400
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On November 19, 2021, Connect Biopharma Holdings Limited (the Company) announced that it has completed full enrollment of its phase 2
clinical trial evaluating CBP-307 in adult patients with moderate-to-severe Ulcerative Colitis.
The information in the first paragraph under Information Contained in this Report on Form 6-K in this
Report on Form 6-K is hereby incorporated by reference into the Companys Registration Statement on Form S-8 (File
No. 333-254524).
On November 19, 2021, the Company issued the press release attached hereto as Exhibit
99.1, which is incorporated herein by reference.
The furnishing of the attached press release is not an admission as to the materiality of any
information therein. The information contained in the press release is summary information that is intended to be considered in the context of more complete information included in the Companys filings with the Securities and Exchange
Commission (the SEC) and other public announcements that the Company has made and may make from time to time. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do
so from time to time as its management believes is appropriate. Any such updating may be made through the filing or furnishing of other reports or documents with the SEC or through other public disclosures.
Exhibit Index
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
Dated: November 19, 2021
|
|
|
|
CONNECT BIOPHARMA HOLDINGS LIMITED
|
|
|
By
|
|
/s/ Eric Hall
|
|
|
|
|
Name:
|
|
Eric Hall
|
|
|
|
|
Title:
|
|
Interim Chief Financial Officer
|
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Mar 2023 to Mar 2024